Jake Hitch

Publications and Insights

• Publication: Patient preferences for treatment in relapsed/refractory acute leukemia
• Insight: Around The World in HTAs: The Slovak Republic – Valuing the Future
• Insight: Setting the Right Discount Rate for HTA in the Slovak Republic
• Insight: Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
• Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
• Insight: Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
• Publication: Supporting the Era of Green Pharmaceuticals in the UK
• Publication: Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
• Insight: Does the New CBO Report Change Anything?
• Insight: Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
• Insight: The CBO Doesn’t Understand Investors
• Insight: H.R. 3 is the Wrong Policy for the Wrong Problem